Novo Nordisk’s GLP-1 agonist Victoza has become the first non-insulin drug to be approved in the US as a treatment for type 2 diabetes in children for almost two decades. The FDA says the okay to use ...
China represents an untapped market for GLP-1 class diabetes drugs, according to Novo Nordisk, which is predicting "good momentum" for its already-approved Victoza, and its successor semaglutide. With ...
Allows you to standardize and centralize the way objects are constructed in your application - symfony/dependency-injection ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback